West Coast Clinical Trials Presentation at 2009 International Conference of the American Thoracic Society

San Diego, CA / May 18, 2009 / - Dr. Kenneth Kim, CEO of West Coast Clinical Trials (WCCT) presented a poster at the International Conference of the American Thoracic Society entitled, "Effect of Adjustable-Dose (AD) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI), Fixed-Dose (FD) Budesonide/Formoterol pMDI, and FD Fluticasone/Salmeterol Dry Powder Inhaler (DPI)  on Predose FEF 25%-75%" .  For additional information regarding this study, please contact AstraZeneca.

About West Coast Clinical Trials, LLC

WCCT is an independent early phase clinical CRO with a 120-bed phase I facility with 10 telemetry equipped beds located in southern California. WCCT has a unique focus on Ethno-bridging studies along with extensive experience with healthy volunteer and specialty trials (allergy, asthma, infectious disease, pediatric, renal and vaccines). For more information, visit our Web site at http://www.wcctrials.com.

_____________________

Contact:


_____________________

Source: West Coast Clinical Trials, LLC